Breaking News

Evotec Earns Roche Milestone in Biomarker Pact

April 24, 2014

Phase I trial to employ prediction marker using Evotec's Proteome platform

Evotec AG has achieved a milestone in its biomarker alliance with Roche. Roche will use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended Phase I oncology trial.
 
This is the first milestone achieved under the collaboration and license agreement signed in 2011. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programs for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
 
Dr. Mario Polywka, chief operating officer of Evotec AG, said, "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.